We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 51

Janssen-Ortho v. Novopharm; merits of 55.2 proceeding; methylphenidate
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 12 2010

The only issue in this proceeding was an allegation of non-infringement and the application for prohibition was dismissed


Mycogen v. Bayer and Monsanto; motion for summary judgment
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 12 2010

Bayer brought a motion for summary judgment on the basis that Monsanto had missed the time set out by the Commissioner under section 43 of the Patent Act to respond to the conflict proceeding


Biovail v. Apotex; merits of 55.2 proceeding; metformin
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 12 2010

The Court dismissed the application for prohibition


Apotex v. Sanofi; interlocutory motion re: affidavits of documents; clopidogrel
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 12 2010

Both parties brought motions for further and better affidavits of documents


AstraZeneca v. Apotex; interlocutory motion for reply evidence; esomeprazole
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 12 2010

The Court dismissed AstraZeneca's appeal from the order of a prothonotary refusing to strike parts of Apotex' evidence and refusing to permit the applicants to file reply


Janssen-Ortho v. Apotex; interlocutory motion for reply evidence; methylphenidate
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 12 2010

In two NOC proceedings, the order of evidence was reversed


Epicept v. Minister of Health; interlocutory motion for confidentiality; histamine
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 12 2010

Epicept has filed for a judicial review of the Minister's decision that its histamine dihydrochloride product is not an innovative drug and is thus not eligible for listing on the register of innovative drugs


Canada (Attorney General) v. Celgene Corporation, appeal of a PMPRB decision
  • Gowling Lafleur Henderson LLP
  • Canada
  • January 20 2010

The Court of Appeal overturned the decision of the Trial Judge and restored the decision of the PMPRB providing jurisdiction to the PMPRB over medicines imported under the Special Access Program


Sanofi-Aventis v. ApotexNovopharmRiva, interlocutory motion to consolidate actions
  • Gowling Lafleur Henderson LLP
  • Canada
  • January 20 2010

Sanofi brought a motion to consolidate three actions pertaining to damages pursuant to section 8 of the NOC Regulations


Pfizer v. Pharmascience, merits of NOC proceeding
  • Gowling Lafleur Henderson LLP
  • Canada
  • January 20 2010

The Court granted prohibition to Pfizer and found that Pharmascience’s allegations of invalidity were not justified